Sai Parenteral'S Profile
Key Indicators
- Authorised Capital ₹ 14.00 Cr
- Paid Up Capital ₹ 13.31 Cr
- Company Age 24 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 111.07 Cr
- Satisfied Charges ₹ 56.42 Cr
- Revenue Growth 7.73%
- Profit Growth -45.31%
- Ebitda 15.77%
- Net Worth 29.55%
- Total Assets 49.16%
About Sai Parenteral'S
Sai Parenteral's Limited (SPL) is a leading Public Limited Indian Non-Government Company incorporated in India on 12 January 2001 and has a history of 24 years and one month. Its registered office is in Rangareddy, Telangana, India.
The Corporate was formerly known as Sai Parenteral's Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 14.00 Cr and a paid-up capital of Rs 13.31 Cr.
The company currently has active open charges totaling ₹111.07 Cr. The company has closed loans amounting to ₹56.42 Cr, as per Ministry of Corporate Affairs (MCA) records.
Aruna Karusala, Anil Karusala, Seeta Gorantla, and Two other members serve as directors at the Company.
Company Details
- Location
Rangareddy, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24231TG2001PLC036043
- Company No.
036043
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
12 Jan 2001
- Date of AGM
29 Dec 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
What products or services does Sai Parenteral's Limited offer?
Sai Parenteral'S Limited offers a wide range of products and services, including Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Anti Infective Drugs & Medicines, Malaria Medicine, Multivitamin Tablets & Capsules, Vitamin B Complex Tablets & Capsules, Pharma Ingredients & Raw Materials, Anti Infective API.
Who are the key members and board of directors at Sai Parenteral'S?
Executive Team (1)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Anil Karusala ![]() | Managing Director | 19-Nov-2021 | Current |
Board Members (4)
Name | Designation | Appointment Date | Status |
---|---|---|---|
Seeta Gorantla ![]() | Director | 20-Feb-2024 | Current |
Aruna Karusala ![]() | Director | 16-Aug-2016 | Current |
Vijitha Gorrepati ![]() | Whole-Time Director | 16-Aug-2016 | Current |
Bhagyashri Zad ![]() | Director | 20-Feb-2024 | Current |
Financial Performance of Sai Parenteral'S.
Sai Parenteral'S Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 7.73% increase. The company also saw a substantial fall in profitability, with a 45.31% decrease in profit. The company's net worth Soared by an impressive increase of 29.55%.


- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
---|---|---|---|---|---|---|---|
Total Revenue |
| ||||||
Revenue from Operations |
| ||||||
Total Assets |
| ||||||
Profit or Loss |
| ||||||
Net Worth |
| ||||||
EBITDA |
|
What is the Ownership and Shareholding Structure of Sai Parenteral'S?
In 2022, Sai Parenteral'S had a promoter holding of 83.92% and a public holding of 16.08%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.

Charges (Loans)
₹111.07 Cr
₹56.42 Cr
Charges Breakdown by Lending Institutions
- Others : 62.98 Cr
- The Hongkong And Shanghai Banking Corporation Limited : 23.00 Cr
- Hdfc Bank Limited : 20.00 Cr
- Sidbi : 5.09 Cr
Latest Charge Details
Date | Lender | Amount | Status |
---|---|---|---|
24 Apr 2024 | Hdfc Bank Limited | ₹20.00 Cr | Open |
21 Jun 2023 | Others | ₹10.00 Cr | Open |
29 Jul 2022 | Others | ₹10.50 Cr | Open |
13 May 2022 | Others | ₹10.00 Cr | Open |
13 May 2022 | Others | ₹10.00 Cr | Open |
How Many Employees Work at Sai Parenteral'S?
Sai Parenteral'S has a workforce of 235 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.

Deals i

Gain comprehensive insights into the Deals and Valuation data of Sai Parenteral'S, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sai Parenteral'S's trajectory.
Rating

Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts

Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.